NEW YORK (Reuters Health) – The selective inhibitor of Janus kinase (JAK) 1 and 2, ruxolitinib, significantly reduces spleen size and other debilitating symptoms in patients with myelofibrosis…
NEW YORK (Reuters Health) – Adding trimetazidine to the treatment of chronic heart failure improves cardiac function and slows left ventricular remodeling, according to the results of a…
NEW YORK (Reuters Health) – Avanafil, another phosphodiesterase type 5 (PDE5) inhibitor, improves sexual function in men with erectile dysfunction, according to a report in the January 16th…
NEW YORK (Reuters Health) – Birth defects are uncommon in offspring of women exposed to leflunomide before conception or in the first trimester of pregnancy, according to a…
NEW YORK (Reuters Health) – There is no need to avoid proton pump inhibitors (PPIs) in patients on the platelet inhibitors clopidogrel or ticagrelor. The increased rates of…
NEW YORK (Reuters Health) – Systematic collection of extensive family history can improve the risk assessment of cardiovascular disease in primary care, according to a report in the…
NEW YORK (Reuters Health) – Results of a study confirm that treatment with dapagliflozin helps patients with type 2 diabetes lose weight in addition to improving their blood…
NEW YORK (Reuters Health) – Sodium phosphate enemas, even in standard doses, may lead to severe metabolic disorders and death in elderly patients, warn clinicians from Israel in…
NEW YORK (Reuters Health) – In the PRIMO trial, treatment with vitamin D2 (paricalcitol) did not improve measures of cardiac structure, function or left ventricular mass in patients…
NEW YORK (Reuters Health) – Results of a population-based observational study indicate that androgen deprivation therapy (ADT) for men with nonmetastatic prostate cancer is associated with an increased…